Artiva Biotherapeutics, Inc. 4

Director Alison Moore received a stock option award for 16,250 shares of Artiva Biotherapeutics, Inc. common stock at a $10.42 exercise price.

On September 10, 2026, director Alison Moore received a stock option grant from Artiva Biotherapeutics, Inc. covering 16,250 shares of common stock at an exercise price of $10.42 per share, classified as an acquisition of a derivative security. The option has a 10-year term expiring on September 9, 2036 and will vest in full on the earlier of September 10, 2027 or the date of the issuer’s 2027 annual stockholder meeting, reflecting a routine director compensation award rather than an open-market transaction. Following this grant, Moore has derivative rights for 16,250 shares, which would represent approximately $169,000 in potential underlying common stock value at the grant price upon full vesting and exercise.

Filing Facts

CIK

1817241

Ticker

ARTV

Form

4

Source Type

fda

Accession

0001193125-26-390524

Alert Tier

5